Mark H. Pollack, M.D.
Associate Professor of Psychiatry, Harvard Medical School
Director, Center for Anxiety and Traumatic Stress Related Disorders

Dr. Pollack is Director of the Center for Anxiety and Traumatic Stress Related Disorders at the Massachusetts General Hospital, and Associate Professor of Psychiatry at Harvard Medical School. He received his M.D. in 1982 from New Jersey Medical School, and completed residency and fellowship training in psychiatry at Massachusetts General Hospital.

Dr. Pollack has received a Faculty Scholar Career Development Award from the National Institute of Mental Health to study the longitudinal course of panic disorder and received funding from the National Institute of Drug Abuse to study the application of cognitive-behavioral interventions for benzodiazepine discontinuation in panic disorder patients to the reduction of illicit drug use in drug abusers. Currently he is principal investigator of an NIMH funded study examining the impact of recent terrorist attacks on the development of PTSD and course of disorder in bipolar patients, and a NIDA funded study examining changes in brain function as assessed by MR Spectroscopy and neuropsychological testing in patients on methadone maintenance. He has published over 200 articles, reviews and chapters, and is co-editor of the books "Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies", “Panic Disorder and Its Treatment,” and “Social Phobia: Research and Practice”. Dr. Pollack serves on numerous editorial and advisory boards, as well as the Scientific Advisory Board of the Anxiety Disorders Association of America, and the Board of Directors of the Mood and Anxiety Disorders Institute of the Massachusetts General Hospital.

His areas of clinical and research interest include the acute and long-term course, pathophysiology and treatment of patients with anxiety disorders and associated comorbidities, development of novel pharmacologic agents for mood and anxiety disorders, uses of combined cognitive-behavioral and pharmacologic therapies for treatment refractory patients, presentation and treatment of anxiety in the medical setting, and the pathophysiology and treatment of substance abuse.